

Item 5.07 Submission of Matters to a Vote of Security Holders.

Enzo Biochem, Inc. (the “Company”) held its Annual Meeting of Shareholders (the “Annual Meeting”) on January 6, 2016. The following matters, all of which were set forth in the Proxy Statement, were voted on at the Annual Meeting. The final results of such voting are as indicated below.

1. Election of the nominees listed below to serve as Class I Directors on the Board of Directors of the Company, to hold office for a term of three (3) years or until their successors have been duly elected and qualified:

| Nominee | Votes For | Withhold | Abstentions | Broker Non-Vote |
|------------------|------------------|-----------------|--------------------|------------------------|
| Gregory M. Bortz | 30,769,099 | 1,247,935 | N/A | 0 |

| | | | | |
|--------------|------------|-----------|-----|---|
| Dov Perlysky | 30,745,788 | 1,271,246 | N/A | 0 |
|--------------|------------|-----------|-----|---|

2. Approve, in a nonbinding advisory vote, the compensation of the Company’s named executive officers:

| | |
|------------------|------------|
| Votes for | 21,731,701 |
| Votes against | 11,497,283 |
| Abstentions | 183,454 |
| Broker Non-Votes | 0 |

3. Ratification of the Company’s appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending July 31, 2016:

| | |
|---------------|------------|
| Votes for | 31,639,712 |
| Votes against | 1,538,724 |
| Abstentions | 234,002 |

Broker Non-Votes 0

On the basis of the above votes, (i) the nominees listed above were elected to serve as Class I Directors on the Board of Directors of the Company, to hold office for a term of three (3) years or until their successors have been duly elected and qualified; (ii) the proposal to approve, in a nonbinding advisory vote, the compensation of the Company’s named executive officers was approved; and (iii) the proposal to ratify the Company’s appointment of EisnerAmper LLP to serve as the Company’s independent registered public accounting firm for the Company’s fiscal year ending July 31, 2016 was approved.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENZO BIOCHEM, INC.

Date: January 8, 2016 By: /s/ Barry W. Weiner
Barry W. Weiner
President
